BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 21768308)

  • 21. Polyamines regulate the stability of activating transcription factor-2 mRNA through RNA-binding protein HuR in intestinal epithelial cells.
    Xiao L; Rao JN; Zou T; Liu L; Marasa BS; Chen J; Turner DJ; Zhou H; Gorospe M; Wang JY
    Mol Biol Cell; 2007 Nov; 18(11):4579-90. PubMed ID: 17804813
    [TBL] [Abstract][Full Text] [Related]  

  • 22. miR-519 suppresses tumor growth by reducing HuR levels.
    Abdelmohsen K; Kim MM; Srikantan S; Mercken EM; Brennan SE; Wilson GM; Cabo Rd; Gorospe M
    Cell Cycle; 2010 Apr; 9(7):1354-9. PubMed ID: 20305372
    [TBL] [Abstract][Full Text] [Related]  

  • 23. RRM1, TUBB3, TOP2A, CYP19A1, CYP2D6: Difference between mRNA and protein expression in predicting prognosis of breast cancer patients.
    Xu YC; Zhang FC; Li JJ; Dai JQ; Liu Q; Tang L; Ma Y; Xu Q; Lin XL; Fan HB; Wang HX
    Oncol Rep; 2015 Oct; 34(4):1883-94. PubMed ID: 26252353
    [TBL] [Abstract][Full Text] [Related]  

  • 24. TOP2A is overexpressed and is a therapeutic target for adrenocortical carcinoma.
    Jain M; Zhang L; He M; Zhang YQ; Shen M; Kebebew E
    Endocr Relat Cancer; 2013 Jun; 20(3):361-70. PubMed ID: 23533247
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The ELAV RNA-stability factor HuR binds the 5'-untranslated region of the human IGF-IR transcript and differentially represses cap-dependent and IRES-mediated translation.
    Meng Z; King PH; Nabors LB; Jackson NL; Chen CY; Emanuel PD; Blume SW
    Nucleic Acids Res; 2005; 33(9):2962-79. PubMed ID: 15914670
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Interaction between 3' untranslated region of calcitonin receptor messenger ribonucleic acid (RNA) and adenylate/uridylate (AU)-rich element binding proteins (AU-rich RNA-binding factor 1 and Hu antigen R).
    Yasuda S; Wada S; Arao Y; Kogawa M; Kayama F; Katayama S
    Endocrinology; 2004 Apr; 145(4):1730-8. PubMed ID: 14715706
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Influence of the RNA-binding protein HuR in pVHL-regulated p53 expression in renal carcinoma cells.
    Galbán S; Martindale JL; Mazan-Mamczarz K; López de Silanes I; Fan J; Wang W; Decker J; Gorospe M
    Mol Cell Biol; 2003 Oct; 23(20):7083-95. PubMed ID: 14517280
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Interplay between RNA-binding protein HuR and microRNA-125b regulates p53 mRNA translation in response to genotoxic stress.
    Ahuja D; Goyal A; Ray PS
    RNA Biol; 2016 Nov; 13(11):1152-1165. PubMed ID: 27592685
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Assessment of Topoisomerase II α status in breast cancer by quantitative PCR, gene expression microarrays, immunohistochemistry, and fluorescence in situ hybridization.
    Romero A; Martín M; Cheang MC; López García-Asenjo JA; Oliva B; He X; de la Hoya M; García Sáenz JÁ; Arroyo Fernández M; Díaz Rubio E; Perou CM; Caldés Llopis T
    Am J Pathol; 2011 Apr; 178(4):1453-60. PubMed ID: 21435434
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Posttranscriptional Regulation of the Inflammatory Marker C-Reactive Protein by the RNA-Binding Protein HuR and MicroRNA 637.
    Kim Y; Noren Hooten N; Dluzen DF; Martindale JL; Gorospe M; Evans MK
    Mol Cell Biol; 2015 Dec; 35(24):4212-21. PubMed ID: 26438598
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Polyamines regulate c-Myc translation through Chk2-dependent HuR phosphorylation.
    Liu L; Rao JN; Zou T; Xiao L; Wang PY; Turner DJ; Gorospe M; Wang JY
    Mol Biol Cell; 2009 Dec; 20(23):4885-98. PubMed ID: 19812253
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Karyotypic imbalances and differential gene expressions in the acquired doxorubicin resistance of hepatocellular carcinoma cells.
    Pang E; Hu Y; Chan KY; Lai PB; Squire JA; Macgregor PF; Beheshti B; Albert M; Leung TW; Wong N
    Lab Invest; 2005 May; 85(5):664-74. PubMed ID: 15765123
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Stabilization of Dll1 mRNA by Elavl1/HuR in neuroepithelial cells undergoing mitosis.
    García-Domínguez DJ; Morello D; Cisneros E; Kontoyiannis DL; Frade JM
    Mol Biol Cell; 2011 Apr; 22(8):1227-39. PubMed ID: 21346194
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A truncated cytoplasmic topoisomerase IIalpha in a drug-resistant lung cancer cell line is encoded by a TOP2A allele with a partial deletion of exon 34.
    Mirski SE; Sparks KE; Yu Q; Lang AJ; Jain N; Campling BG; Cole SP
    Int J Cancer; 2000 Feb; 85(4):534-9. PubMed ID: 10699927
    [TBL] [Abstract][Full Text] [Related]  

  • 35. ERK8 is a novel HuR kinase that regulates tumour suppressor PDCD4 through a miR-21 dependent mechanism.
    Liwak-Muir U; Dobson CC; Naing T; Wylie Q; Chehade L; Baird SD; Chakraborty PK; Holcik M
    Oncotarget; 2016 Jan; 7(2):1439-50. PubMed ID: 26595526
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Alternative polyadenylation variants of the RNA binding protein, HuR: abundance, role of AU-rich elements and auto-Regulation.
    Al-Ahmadi W; Al-Ghamdi M; Al-Haj L; Al-Saif M; Khabar KS
    Nucleic Acids Res; 2009 Jun; 37(11):3612-24. PubMed ID: 19359363
    [TBL] [Abstract][Full Text] [Related]  

  • 37. HER2 and TOP2A in high-risk early breast cancer patients treated with adjuvant epirubicin-based dose-dense sequential chemotherapy.
    Fountzilas G; Valavanis C; Kotoula V; Eleftheraki AG; Kalogeras KT; Tzaida O; Batistatou A; Kronenwett R; Wirtz RM; Bobos M; Timotheadou E; Soupos N; Pentheroudakis G; Gogas H; Vlachodimitropoulos D; Polychronidou G; Aravantinos G; Koutras A; Christodoulou C; Pectasides D; Arapantoni P
    J Transl Med; 2012 Jan; 10():10. PubMed ID: 22240029
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Regulation of Poly(A) Tail and Translation during the Somatic Cell Cycle.
    Park JE; Yi H; Kim Y; Chang H; Kim VN
    Mol Cell; 2016 May; 62(3):462-471. PubMed ID: 27153541
    [TBL] [Abstract][Full Text] [Related]  

  • 39. miR-29 acts as a decoy in sarcomas to protect the tumor suppressor A20 mRNA from degradation by HuR.
    Balkhi MY; Iwenofu OH; Bakkar N; Ladner KJ; Chandler DS; Houghton PJ; London CA; Kraybill W; Perrotti D; Croce CM; Keller C; Guttridge DC
    Sci Signal; 2013 Jul; 6(286):ra63. PubMed ID: 23901138
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Simultaneous amplification of HER-2 (ERBB2) and topoisomerase IIalpha (TOP2A) genes--molecular basis for combination chemotherapy in cancer.
    Järvinen TA; Liu ET
    Curr Cancer Drug Targets; 2006 Nov; 6(7):579-602. PubMed ID: 17100565
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.